Efficacy and dynamics of self-targeting CRISPR/Cas constructs for gene editing in the retina.
Li FaniD, Sandy S. C. HungiD, Mohd Khairul Nizam Mohd KhalidiD, Jiang-Hui WangiD, Vicki ChrysostomouiD, Vickie H. Y. WongiD, Vikrant Singh, Kristof WingiD, Leilei Tu, James A. Bender, Alice PébayiD, Anna Elizabeth KingiD, Anthony L. CookiD, Raymond C.B. WongiD, Bang Viet BuiiD, Alex William HewittiD, Guei‐Sheung LiuiD
Abstract
Safe delivery of CRISPR/Cas endonucleases remains one of the major barriers to the widespread application of in vivo genome editing including the anticipatory treatment of monogenic retinal diseases. We previously reported the utility of adeno-associated virus (AAV)-mediated CRISPR/Cas genome editing in the retina; however, with this type of viral delivery system, active endonucleases will remain in the retina for an extended period, making genotoxicity a significant consideration in clinical applications. To address this issue, we have designed a self-destructing \"kamikaze\" CRISPR/Cas system that disrupts the Cas enzyme itself following expression. Four guide RNAs (sgRNAs) were designed to target Streptococcus pyogenes Cas9 (SpCas9), after in situ validation, the selected sgRNAs were cloned into a dual AAV vector. One construct was used to deliver SpCas9 and the other delivered sgRNAs directed against SpCas9 and the target locus (yellow fluorescent protein, YFP), in the presence of mCherry. Both constructs were packaged into AAV2 vector and intravitreally administered in C57BL/6 and Thy1-YFP transgenic mice. After 8 weeks the expression of SpCas9, the efficacy of YFP gene disruption was quantified. A reduction of SpCas9 mRNA was found in retinas treated with AAV2-mediated-YFP/SpCas9 targeting CRISPR/Cas compared to those treated with YFP targeting CRISPR/Cas alone. We also show that AAV2-mediated delivery of YFP/SpCas9 targeting CRISPR/Cas significantly reduced the number of YFP fluorescent cells among mCherry-expressing cells (~85.5% reduction compared to LacZ/SpCas9 targeting CRISPR/Cas) in transfected retina of Thy1-YFP transgenic mice. In conclusion, our data suggest that a self-destructive \"kamikaze\" CRISPR/Cas system can be used as a robust tool for refined genome editing in the retina, without compromising on-target efficiency.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 24
- FWCI
- 1.49
- Field percentile
- top 18%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparison of CRISPR/Cas endonucleases for in vivo retinal gene editing.
F. Li, K. Wing, … A. W. Hewitt·bioRxiv·Jun 9, 2020
- AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo.
Sandy SC Hung, Vicki Chrysostomou, … Alex Hewitt·Investigative Opthalmology & Visual SciencePeer-reviewed·Jun 29, 2016
- Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina
C. Botto, J. Pulman, … D. Dalkara·bioRxiv·Oct 16, 2023
- AAV-delivered CRISPR-Cas9 elicits persistent retinal immune responses compared with transient responses to RNP
Juliette Pulman, Duohao Ren, … Sylvain Fisson·bioRxiv·Dec 14, 2025
- Characterisation of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina
Satheesh Kumar, Yi-Wen Hsiao, … Guei‐Sheung Liu·Proceedings of the National Academy of SciencesPeer-reviewed·Oct 30, 2024
- Engineering single-AAV CRISPR-Cas13 RNA base editors for treatment of inherited retinal diseases
Satheesh Kumar, Heng-Ai Chang, … Guei‐Sheung Liu·bioRxiv·Aug 6, 2025